Effects of chronic acetylsalicylate administration on several nutritional and biochemical parameters in rats fed diets of varied thiamin content

Mackerer, Carl R.; Mehlman, Myron A.; Tobin, Richard B.

doi:10.1016/0006-2944(73)90008-2

Cited by 4 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…such as iron, zinc, biotin, vitamin B6, pantothenic acid, and copper [274], would then be required with an increased need-as mitochondria produce around 40 kg of ATP each day [270]. Compensatory mechanisms were revealed in animals [275], and inadequate micronutrient intake would result in further mitochondrial decay [39,274,276]. The clinical relevance of the mechanism in humans has yet to be assessed.…”

Section: Asa and Metabolic Misuse Of Micronutrientsmentioning

confidence: 99%

Potential Drug–Nutrient Interactions of 45 Vitamins, Minerals, Trace Elements, and Associated Dietary Compounds with Acetylsalicylic Acid and Warfarin—A Review of the Literature

Renaud,

Höller,

Michel

2024

Nutrients

View full text Add to dashboard Cite

In cardiology, acetylsalicylic acid (ASA) and warfarin are among the most commonly used prophylactic therapies against thromboembolic events. Drug–drug interactions are generally well-known. Less known are the drug–nutrient interactions (DNIs), impeding drug absorption and altering micronutritional status. ASA and warfarin might influence the micronutritional status of patients through different mechanisms such as binding or modification of binding properties of ligands, absorption, transport, cellular use or concentration, or excretion. Our article reviews the drug–nutrient interactions that alter micronutritional status. Some of these mechanisms could be investigated with the aim to potentiate the drug effects. DNIs are seen occasionally in ASA and warfarin and could be managed through simple strategies such as risk stratification of DNIs on an individual patient basis; micronutritional status assessment as part of the medical history; extensive use of the drug–interaction probability scale to reference little-known interactions, and application of a personal, predictive, and preventive medical model using omics.

show abstract